ABIS-45RC treatment preserves elimination of tumor cells by GVT and memory antiviral immune responses. (A) NSG mice were injected subcutaneously with human MDA-MB-231 breast cancer cells and, when tumor growth was detectable (day 8), were transferred with total human PBMCs to induce GVT. Results are expressed in tumor volume (left) and mice survival (right) (2 experiments). *P < .05; **P < .01. (B) Human PBMCs from CMV⁺ or CMV⁻ individuals were cultured in medium, with CMV peptides or SEB superantigen with or without ABIS-45RC mAb (n = 7). Cytokine responses were analyzed by flow cytometry on CD4⁺ and CD8⁺ T cells (1 experiment). (C) TNF-α release by human PBMCs from healthy volunteers cultured for 24 hours with PBMCs at low (10⁶ cells per well) or high density (10⁷ cells per well precultured for the previous 24 hours) with ABIS-45RC, isotype control, OKT3 mAbs, or unstimulated. TNF-α release was detected by applying the Ella-system assay (1 experiment).